Context-specific applications of CARM1 inhibitors: functional profiles of EZM2302 and TP-064
Yena Cho1,2, Yong Kee Kim3,4
1Muscle Physiome Research Center and Research Institute of Pharmaceutical Sciences, Sookmyung Women's University, Seoul, 04310, Republic of Korea.
Background:
Coactivator-associated arginine methyltransferase 1 (CARM1) regulates diverse cellular processes-including transcription, cell cycle progression, metabolism, and autophagy-through asymmetric dimethylation of both histone and non-histone substrates. Although TP-064 and EZM2302 both inhibit CARM1, they may elicit distinct biological effects.
Methods:
We employed immunoblotting, subcellular fractionation, histone extraction, chromatin immunoprecipitation assay, quantitative PCR, and confocal microscopy to compare the effects of TP-064 and EZM2302. Substrate methylation and autophagic responses were evaluated under nutrient-deprived conditions.
Results:
Both TP-064 and EZM2302 inhibited CARM1-dependent methylation of non-histone substrates, including p300, GAPDH, and DRP1. However, TP-064 markedly reduced nuclear histone methylation marks H3R17me2a and H3R26me2a, whereas EZM2302 had minimal effect on these epigenetic modifications. Reflecting this differential impact, TP-064-but not EZM2302-suppressed transcription of autophagy-related genes and impaired LC3 lipidation and puncta formation under glucose deprivation. Consequently, TP-064 sensitized cells to energy stress by disrupting autophagic flux. These findings indicate that TP-064 inhibits both nuclear and cytoplasmic functions of CARM1, while EZM2302 selectively targets non-histone methylation events.
Conclusion:
Our study reveals fundamental mechanistic differences between TP-064 and EZM2302 in regulating CARM1 substrates and downstream pathways. This substrate-selective inhibition has important implications for experimental design and therapeutic development, underscoring the need for context-specific selection of CARM1 inhibitors in both basic research and precision medicine.
Insights
TP-064 and EZM2302 inhibit CARM1, but TP-064 also affects histone methylation and autophagy, unlike EZM2302. This substrate-selective inhibition impacts CARM1
Area of Science:
- Epigenetics and Molecular Biology
- Cellular Metabolism
- Drug Discovery
Background:
- Coactivator-associated arginine methyltransferase 1 (CARM1) is a key regulator of transcription, cell cycle, metabolism, and autophagy.
- CARM1's diverse functions stem from its ability to methylate both histone and non-histone substrates.
- TP-064 and EZM2302 are known CARM1 inhibitors with potentially distinct biological effects.
Purpose of the Study:
- To compare the mechanistic differences between TP-064 and EZM2302 in inhibiting CARM1.
- To investigate the substrate selectivity and downstream effects of each inhibitor.
- To evaluate their impact on histone methylation and autophagic responses.
Main Methods:
- Immunoblotting, subcellular fractionation, and chromatin immunoprecipitation assays were used.
- Quantitative PCR and confocal microscopy assessed gene transcription and protein localization.
- Autophagic responses were evaluated under nutrient-deprived conditions.
Main Results:
- Both TP-064 and EZM2302 inhibited methylation of non-histone substrates like p300, GAPDH, and DRP1.
- TP-064 significantly reduced histone methylation marks (H3R17me2a, H3R26me2a), while EZM2302 had minimal impact.
- TP-064 suppressed autophagy-related gene transcription and impaired autophagic flux, unlike EZM2302.
Conclusions:
- TP-064 inhibits both nuclear and cytoplasmic CARM1 functions, affecting histone methylation and autophagy.
- EZM2302 selectively targets non-histone methylation events, with less impact on epigenetic modifications.
- Substrate-selective inhibition by CARM1 inhibitors necessitates context-specific selection for research and therapeutic applications.
